Revised criteria for the diagnosis of mild cognitive impairment (MCI) could compromise the diagnosis of Alzheimer disease (AD) dementia, according to an analysis published online Feb. 6 in Archives of Neurology.
TRIUMF, Canada's national laboratory for particle and nuclear physics, has begun building a tunnel and lab that will be used to demonstrate new ways to solve medical isotope shortages.
The Centre for Addiction and Mental Health (CAMH) in Toronto will open the doors to its new Research Imaging Centre, where PET, MRI and genetic imaging will be focused on the study of addictions and mental illness.
Columbia University's engineering researchers have developed a technique that utilizes extremely short pulses of ultrasound waves to open the blood-brain barrier, creating a host of possibilities for noninvasively treating brain disorders such as Alzheimer’s disease, Parkinson’s disease, atypical lobular hyperplasia and epilepsy.
McMaster University in Hamilton, Ontario, has unveiled its newly expanded Nuclear Research Building, which includes a new cyclotron facility and improvements to the McMaster Nuclear Reactor (MNR) Building.
NeuroLogica has received CE Mark approval for its portable inSPira HD SPECT camera.
Individuals with deterministic genes in whom it is known that Alzheimer’s disease (AD) will develop appear to show differences in beta-amyloid distribution when compared with non-dominantly inherited AD patients, helping to consolidate evidence that PET and MRI can depict brain changes well before the arrival of AD-related symptoms, according to preliminary findings presented July 20 at the 2011 Alzheimer’s Association International Conference in Paris.
Known to be significantly more susceptible to dementia, individuals with Down syndrome appear to display age-related increases in amyloid senile plaques and tau neurofibrillary tangles that mirror those increases in Alzheimer’s patients as viewed with PET, according to a study published in the June issue of Archives of Neurology.
A new 3D x-ray method, SAXS-CT, offers detailed images of brain cells and maps the myelin sheaths of nerve cells, which are key to understanding conditions such as multiple sclerosis and Alzheimer's disease, according to Danish research published in the July issue of NeuroImage.
Consumer advocacy organization Public Citizen has submitted a letter to the editor to the Journal of the American Medical Association, criticizing the Clark et al study, published Jan. 19, which reported a strong quantitative correlation between the biomarker florbetapir F18's signal on PET scans and the presence of beta-amyloid in the brain at death, suggesting that imaging biomarkers may be applied for diagnosing and determining early risks for Alzheimer's disease.
Written by C.P. Kaiser
Last year, the SNM received a $48,000 grant from the Agency for Healthcare Research and Quality to develop comparative-effectiveness research (CER) of PET and other molecular imaging techniques. The primary emphasis is on the diagnosis and management of cancer patients, but both cardiology and neurology questions are being addressed. Far beyond the dollars, too, is a significant increase in intellectual capital being expended across the globe on the role of CER in molecular imaging.
For the first time in 27 years, the Alzheimer’s Association and the National Institute on Aging (NIA) have published new criteria for the diagnosis of Alzheimer’s disease, offering a general framework for early diagnosis but considering existing research unripe for definitive pre-clinical criteria.
Significant elevations in blood levels of amyloid beta 42 peptide, were detected by Single Molecule Array (SiMoA) technology in patients who experienced hypoxia following cardiac arrest, according to results presented this week at the American Academy of Neurology annual meeting held in Honolulu.
The Alzheimer's Drug Discovery Foundation, based in New York City, will provide Melbourne, Australia-based Prana Biotechnology an investment of $700,000 over two years to conduct a clinical trial investigating the potential of PBT2 to reduce the accumulation of beta-amyloid in the brain of people with Alzheimer's disease. PET amyloid neuroimaging and other biomarkers will be used as the primary outcome measures.
Eli Lilly and its wholly owned subsidiary, Avid Radiopharmaceuticals, have received a complete response letter from the FDA for their new drug application (NDA), denying the approval of florbetapir F-18 injection (Amyvid), a PET imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients, citing concerns about reader interpretation training.
|
RSS 
